February 7, 2018 07:55 AM ESTUpdated February 9, 06:33 AM

North of a billion biotech VC dollars to come from C-Bridge, Rothschild as global biopharma capital flows

Amber Tong

Two powerhouse private equity firms, based out of Europe and China respectively, are looking at multi-million funds to fuel their global biopharma pursuits.

France’s Edmond …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

North of a billion biotech VC dollars to come from C-Bridge, Rothschild as global biopharma capital flows

Amber Tong

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

North of a bil­lion biotech VC dol­lars to come from C-Bridge, Roth­schild as glob­al bio­phar­ma cap­i­tal flows

Amber Tong

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

North of a billion biotech VC dollars to come from C-Bridge, Rothschild as global biopharma capital flows

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA